CDEK
← All drugs Report issue

cediranib

Small moleculeexperimental

Cediranib is a potent inhibitor of vascular endothelial growth factor (VEGF) receptor tyrosine kinases. — Wikipedia

Clinical trial activity

104 trials · 60 clinical orgs · 0 marketing orgs

Phase 1
36
Phase 2
68
Phase 3
10
Phase 4
0

Earliest trial started Feb 1, 2003 (NCT00501605)

Timeline

2000s

  1. Jan 1, 2003

    Earliest Phase 1 Sponsor(trial)

  2. Jan 1, 2005

    Earliest Phase 2 Sponsor(trial)

  3. Jan 1, 2006

    Earliest Phase 3 Sponsor(trial)

Indications

Studied for

Mechanism of action

Chemistry & pharmacology

Loading structure…

SMILES

COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1
Mol. weight
450.51 g/mol
Lipinski Ro5
1 violation(s)
Rule of 3
No
Chirality
Achiral Molecule
Inorganic
No
Polymer
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • 4-((4-fluoro-2-methyl-1h-indol-5-yl)oxy)-6-methoxy-7-(3-(pyrrolidin-1-yl)propoxy)quinazoline
  • azd2171
  • azd2171
  • azd2171
  • azd 2171
  • azd-2171
  • azd-2171
  • azd-2171
  • cediranib
  • cediranib
  • cediranib
  • cediranib
  • cediranib
  • cediranib maleate
  • cediranib maleate
  • cediranib maleate
  • recentin
  • recentin
  • recentin
  • zd-2171
  • zd-2171

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT04739800Phase 2Apr 28, 2021National Cancer Institute (NCI), NRG Oncology
NCT04184518Phase 2Feb 29, 2020Grupo Español Multidisciplinar de Melanoma, Institut Català d'Oncologia, MFAR Clinical Research
NCT04090567Phase 2Dec 5, 2019National Cancer Institute (NCI), University of Texas at Houston
NCT03741426Phase 2Jul 25, 2019AstraZeneca, Cancer Research UK, University of Cambridge
NCT03851614Phase 2Apr 8, 2019AstraZeneca, University of Toronto
NCT03699449Phase 2Nov 26, 2018AstraZeneca, Korean Gynecologic Oncology Group, Seoul National University, Sungkyunkwan University, Yonsei University
NCT04487587Phase 2Oct 9, 2018University of Liverpool
NCT03660826Phase 2Sep 4, 2018National Cancer Institute (NCI), NRG Oncology
NCT03570437Phase 2May 17, 2018AstraZeneca, Cardiff University, The Christie NHS Foundation Trust, University of Manchester
NCT03278717Phase 3Dec 31, 2017University of London
NCT03334617Phase 2Dec 18, 2017AstraZeneca, University of Texas at Houston
NCT02974621Phase 2Sep 15, 2017Harvard University, National Cancer Institute (NCI)
NCT03314740Phase 2Jun 1, 2017AstraZeneca, Mario Negri Institute, University of Milan
NCT02899728Phase 2Apr 7, 2017Harvard University, National Cancer Institute (NCI)
NCT03117933Phase 2Mar 9, 2017AstraZeneca, University of Oxford
NCT02889900Phase 2Jan 17, 2017AstraZeneca, Myrexis Inc., National Cancer Institute (NCI), National Institutes of Health (NIH)
NCT02893917Phase 2Dec 23, 2016National Cancer Institute (NCI), Yale University
NCT02855697Early Phase 1 (Phase 1)Nov 1, 2016The Christie NHS Foundation Trust
NCT02681237N/AApr 29, 2016AstraZeneca, University of Toronto
NCT02498613Phase 2Apr 26, 2016AstraZeneca, National Cancer Institute (NCI), Yale University
Showing 20 of 104 trials
Page 1 / 6

Organizations

Research & Development (60)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
National Cancer Institute (NCI)Government514942005
AstraZenecaFor profit453042003
Harvard UniversityAcademic/Hospital14132005
University of TorontoAcademic/Hospital9332005
NRG OncologyAcademic/Hospital6022010
Canadian Cancer Trials GroupAcademic/Hospital5422005
University of LondonAcademic/Hospital5422007
The Christie NHS Foundation TrustAcademic/Hospital4232010
University of OttawaAcademic/Hospital4022005
University of Texas at HoustonAcademic/Hospital4122007
Cancer Research UKAcademic/Hospital3032007
Mayo ClinicAcademic/Hospital3022006
Royal Marsden Hospital NHS TrustAcademic/Hospital3022005
University of ChicagoAcademic/Hospital3012005
Wayne State UniversityAcademic/Hospital3022005
National Institutes of Health (NIH)Government2012007
North Central Cancer Treatment GroupAcademic/Hospital2012005
Radboud UniversityAcademic/Hospital2122008
Southwest Oncology GroupAcademic/Hospital2012005
Yale UniversityAcademic/Hospital2012016
60 organizations
Page 1 / 3